Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

NCT02147990 is registered in ClinicalTrials.gov with Clovis Oncology, Inc. as lead sponsor.

NCT NCT02147990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02147990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Clovis Oncology, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 16, 2014
Completion date
August 27, 2019
Enrollment
318 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer